| Identification | Back Directory | [Name]
PQM130 | [CAS]
2089415-51-8 | [Synonyms]
PQM130
Inhibitor,PQM-130,Amyloid-β,β-amyloid peptide,Abeta,PQM130,PQM 130,inhibit | [Molecular Formula]
C23H27NO4 | [MDL Number]
MFCD32174292 | [MOL File]
2089415-51-8.mol | [Molecular Weight]
381.46 |
| Chemical Properties | Back Directory | [Boiling point ]
525.3±40.0 °C(Predicted) | [density ]
1.174±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.75±0.31(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget drug candidate against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD drug development[1].
PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) [1]. Animal Model: Adult male C57Bl/6 mice (9 weeks old, 25-30 g body weight) [1]. | [References]
[1]. Morroni F, et al. PQM130, a Novel Feruloyl-Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer's Disease. Front Pharmacol. 2019 Jun 12;10:658. |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|